Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.53 |
| ▸ | RAB9A | P51151 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | NAMPT | P43490 | 7/20 | 0.50 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4767921 | 0.90 | NPC1 (0.56) | NPC1RAB9AMAPTNAMPTMCHR1 | |
| SCHEMBL4765684 | 0.88 | NAMPT (0.47) | NPC1RAB9AMAPTNAMPTCYP3A4 | |
| SCHEMBL4772427 | 0.87 | CCR2 (0.46) | NPC1MAPTNAMPTCYP3A4CYP2D6 | |
| SCHEMBL4774355 | 0.85 | HRH3 (0.57) | NAMPTCYP2D6HRH3 | |
| SCHEMBL4771050 | 0.85 | CYP3A4 (0.56) | NPC1RAB9AMAPTNAMPTCYP3A4 | |
| SCHEMBL14440719 | 0.84 | NAMPT (0.44) | NPC1RAB9ANAMPTCYP3A4CYP2D6 | |
| SCHEMBL4767666 | 0.84 | CYP3A4 (0.58) | NPC1RAB9AMAPTNAMPTCYP3A4 | |
| SCHEMBL4767933 | 0.82 | RAB9A (0.52) | NPC1RAB9ANAMPTCYP3A4CYP2D6 | |
| SCHEMBL5458802 | 0.82 | CA12 (0.56) | NPC1RAB9AMAPTNAMPTKMT2A | |
| SCHEMBL10247726 | 0.81 | HRH3 (0.62) | NAMPTCYP2D6HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1713778-B1 | BENZAZEPINE DERIVATIVES AS HISTAMINE H3 ANTAGONISTS | GLAXO GROUP LTD (GB) | 2008-01-16 | — | — | EP | claimed |
| US-20070060566-A1 | Benzazepine derivatives as histamine h3 antagonists | GLAXO GROUP LIMITED (GB) | 2007-03-15 | — | — | US | claimed |
| EP-1713778-B1 | BENZAZEPINE DERIVATIVES AS HISTAMINE H3 ANTAGONISTS | GLAXO GROUP LTD (GB) | 2008-01-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060566-A1 | Benzazepine derivatives as histamine h3 antagonists | HRH3, HRH4, HRH1 | NPC1 2009/4885RAB9A 2307/4885MAPT 405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.